-DOCSTART- -X- O
Japanese -X- _ B-Patient
encephalitis -X- _ I-Patient
is -X- _ O
a -X- _ O
zoonotic -X- _ O
disease -X- _ O
caused -X- _ O
by -X- _ O
the -X- _ O
Japanese -X- _ O
encephalitis -X- _ O
virus -X- _ O
( -X- _ O
JEV -X- _ O
) -X- _ O
. -X- _ O
It -X- _ O
is -X- _ O
mainly -X- _ O
epidemic -X- _ O
in -X- _ O
Asia -X- _ O
with -X- _ O
an -X- _ O
estimated -X- _ O
69,000 -X- _ O
cases -X- _ O
occurring -X- _ O
per -X- _ O
year. -X- _ O
However -X- _ O
, -X- _ O
no -X- _ O
approved -X- _ O
agents -X- _ O
are -X- _ O
available -X- _ O
for -X- _ O
the -X- _ O
treatment -X- _ O
of -X- _ O
JEV -X- _ B-Patient
infection -X- _ I-Patient
, -X- _ O
and -X- _ O
existing -X- _ O
vaccines -X- _ O
can -X- _ O
not -X- _ O
control -X- _ O
various -X- _ O
types -X- _ O
of -X- _ O
JEV -X- _ O
strains. -X- _ O
Drug -X- _ O
repurposing -X- _ O
is -X- _ O
a -X- _ O
new -X- _ O
concept -X- _ O
for -X- _ O
finding -X- _ O
new -X- _ O
indication -X- _ O
of -X- _ O
existing -X- _ O
drugs -X- _ O
, -X- _ O
and -X- _ O
, -X- _ O
recently -X- _ O
, -X- _ O
the -X- _ O
concept -X- _ O
has -X- _ O
been -X- _ O
used -X- _ O
to -X- _ O
discover -X- _ O
new -X- _ O
antiviral -X- _ O
agents. -X- _ O
Identifying -X- _ O
host -X- _ O
proteins -X- _ O
involved -X- _ O
in -X- _ O
the -X- _ O
progress -X- _ O
of -X- _ O
JEV -X- _ O
infection -X- _ O
and -X- _ O
using -X- _ O
these -X- _ O
proteins -X- _ O
as -X- _ O
targets -X- _ O
are -X- _ O
the -X- _ O
center -X- _ O
of -X- _ O
drug -X- _ O
repurposing -X- _ O
for -X- _ O
JEV -X- _ B-Patient
infection. -X- _ I-Patient
In -X- _ O
this -X- _ O
study -X- _ O
, -X- _ O
based -X- _ O
on -X- _ O
the -X- _ O
gene -X- _ O
expression -X- _ O
data -X- _ O
of -X- _ O
JEV -X- _ O
infection -X- _ O
and -X- _ O
the -X- _ O
phenome-wide -X- _ O
association -X- _ O
study -X- _ O
( -X- _ O
PheWAS -X- _ O
) -X- _ O
data -X- _ O
, -X- _ O
we -X- _ O
identified -X- _ O
286 -X- _ B-Outcome
genes -X- _ I-Outcome
that -X- _ I-Outcome
participate -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
progress -X- _ I-Outcome
of -X- _ I-Outcome
JEV -X- _ I-Outcome
infection -X- _ I-Outcome
using -X- _ I-Outcome
systems -X- _ I-Outcome
biology -X- _ I-Outcome
methods. -X- _ I-Outcome
The -X- _ O
enrichment -X- _ O
analysis -X- _ O
of -X- _ O
these -X- _ O
genes -X- _ O
suggested -X- _ O
that -X- _ O
the -X- _ O
genes -X- _ O
identified -X- _ O
by -X- _ O
our -X- _ O
methods -X- _ O
were -X- _ O
predominantly -X- _ O
related -X- _ O
to -X- _ O
viral -X- _ O
infection -X- _ O
pathways -X- _ O
and -X- _ O
immune -X- _ O
response-related -X- _ O
pathways. -X- _ O
We -X- _ O
found -X- _ O
that -X- _ O
bortezomib -X- _ B-Outcome
, -X- _ I-Outcome
which -X- _ I-Outcome
can -X- _ I-Outcome
target -X- _ I-Outcome
these -X- _ I-Outcome
genes -X- _ I-Outcome
, -X- _ I-Outcome
may -X- _ I-Outcome
have -X- _ I-Outcome
an -X- _ I-Outcome
effect -X- _ I-Outcome
on -X- _ I-Outcome
the -X- _ I-Outcome
treatment -X- _ I-Outcome
of -X- _ I-Outcome
JEV -X- _ I-Outcome
infection. -X- _ I-Outcome
Subsequently -X- _ O
, -X- _ O
we -X- _ O
evaluated -X- _ O
the -X- _ O
antiviral -X- _ O
activity -X- _ O
of -X- _ O
bortezomib -X- _ B-Intervention
using -X- _ O
a -X- _ O
JEV-infected -X- _ B-Patient
mouse -X- _ I-Patient
model. -X- _ I-Patient
The -X- _ O
results -X- _ O
showed -X- _ O
that -X- _ O
bortezomib -X- _ B-Outcome
can -X- _ I-Outcome
lower -X- _ I-Outcome
JEV-induced -X- _ I-Outcome
lethality -X- _ I-Outcome
in -X- _ I-Outcome
mice -X- _ I-Outcome
, -X- _ I-Outcome
alleviate -X- _ I-Outcome
suffering -X- _ I-Outcome
in -X- _ I-Outcome
JEV-infected -X- _ I-Outcome
mice -X- _ I-Outcome
and -X- _ I-Outcome
reduce -X- _ I-Outcome
the -X- _ I-Outcome
damage -X- _ I-Outcome
in -X- _ I-Outcome
brains -X- _ I-Outcome
caused -X- _ I-Outcome
by -X- _ I-Outcome
JEV -X- _ I-Outcome
infection. -X- _ I-Outcome
This -X- _ O
work -X- _ O
provides -X- _ O
an -X- _ O
agent -X- _ O
with -X- _ O
new -X- _ O
indication -X- _ O
to -X- _ O
treat -X- _ O
JEV -X- _ O
infection -X- _ O
. -X- _ O

